AI In Precision Medicine Market Analysis, Size, and Forecast 2025-2029: North America (US and Canada), Europe (France, Germany, Italy, and UK), APAC (China, India, Japan, and South Korea), and Rest of World (ROW)

AI In Precision Medicine Market Size 2025-2029

The AI in precision medicine market size is forecast to increase by USD 880.7 million, at a CAGR of 21.3% between 2024 and 2029.

• The market is driven by the proliferation of large-scale, multi-modal healthcare data and the ascendancy of generative AI in drug discovery and development. The availability of vast amounts of healthcare data, including genomic, proteomic, and clinical data, has created opportunities for AI applications in precision medicine. This data-driven approach enables personalized treatment plans based on individual genetic makeup, lifestyle factors, and disease history. Moreover, generative AI, a subset of AI that can create new data, is increasingly being used in drug discovery and development.
• However, the market faces challenges, including data privacy, security, and governance. With the increasing use of patient data in AI applications, ensuring data security and privacy is crucial. Additionally, establishing clear guidelines for data ownership and access is essential to build trust and ensure ethical use of patient data. Companies seeking to capitalize on market opportunities must navigate these challenges effectively, focusing on data security, transparency, and regulatory compliance.

What will be the Size of the AI In Precision Medicine Market during the forecast period?

Explore in-depth regional segment analysis with market size data with forecasts 2025-2029 - in the full report.
Request Free Sample

• The market for AI in precision medicine continues to evolve, with applications spanning various sectors. Radiomics feature extraction and decision support systems are increasingly utilized for disease risk prediction and diagnostic accuracy improvement. Data visualization tools facilitate the interpretation of complex medical data, while bias mitigation AI ensures evidence-based medicine remains unbiased. Clinical workflow improvement, genetic risk assessment, and digital pathology analysis are also significant areas of growth. Data privacy regulations and ethical considerations are essential as AI is integrated into clinical trials, biomarker validation studies, and pharmacovigilance. The integration of AI algorithms into medical image segmentation, rare disease diagnostics, and drug efficacy prediction is driving innovation.
• The market is expected to grow by over 40% in the next five years, with ongoing activities centered around clinical trial simulation, sensor data fusion, treatment pathway optimization, telemedicine platform integration, model interpretability, drug target identification, oncology clinical trials, and personalized cancer therapy. AI's role in patient stratification, clinical outcome prediction, and pharmacovigilance is also gaining traction. For instance, a recent study reported a 25% increase in diagnostic accuracy using AI algorithms for medical image analysis.

How is this AI In Precision Medicine Market segmented?

The AI in precision medicine market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029,for the following segments.

• Application
  • Oncology
  • Pharmacogenomics
  • Rare disease diagnostics
  • Immunology
  • Neurology
• Technology
  • Deep learning
  • Natural language processing
  • Context-aware processing
  • Reinforcement learning
  • Generative adversarial networks
• End-user
  • Biopharmaceutical
  • Academic and research institutes
  • Hospitals and clinics
  • Contract research organizations
  • Diagnostic laboratories
• Geography
  • North America
    • US
    • Canada
  • Europe
    • France
    • Germany
    • Italy
    • UK
  • APAC
    • China
    • India
    • Japan
    • South Korea
  • Rest of World (ROW)

By Application Insights

The Oncology segment is estimated to witness significant growth during the forecast period. The integration of artificial intelligence (AI) in the precision medicine market, particularly in the oncology segment, is experiencing significant growth and innovation. This advancement is largely driven by the vast and intricate data generated in cancer research and clinical care, necessitating more effective, personalized therapeutic approaches. AI applications span the entire cancer care continuum, from enhancing diagnostic accuracy and efficiency through AI-powered medical imaging and natural language processing, to optimizing treatment selection with predictive modeling and precision oncology treatment. Moreover, AI is revolutionizing disease progression modeling, treatment response monitoring, and drug discovery through deep learning biomarkers, genomic sequencing analysis, and federated learning healthcare.

The AI in Precision Medicine Market is rapidly expanding, driven by the demand for tailored healthcare solutions. Technologies such as machine learning diagnostics and AI-driven drug discovery are transforming disease detection and treatment. Through personalized medicine protocols, clinicians can develop personalized treatment plans for chronic diseases, improving outcomes and reducing trial-and-error prescriptions. A key enabler is genomic data integration for personalized medicine, which allows more accurate disease targeting. With drug response prediction, AI can determine how individuals will react to specific medications. To ensure privacy, patient data anonymization and differential privacy methods are critical, especially when handling sensitive data through big data analytics healthcare platforms.

For instance, AI algorithms have been shown to improve the accuracy of lung cancer diagnosis by up to 95% when compared to traditional methods. The global precision medicine market in oncology is expected to grow by over 25% annually, underscoring the immense potential and impact of AI in transforming cancer care.

Get Key Insights on Market Forecast (PDF)- Request Free Sample

Regional Analysis

North America is estimated to contribute 44% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

See How AI in precision medicine market Demand is Rising in North America Request Free Sample

The market is experiencing significant growth in North America, driven by a sophisticated healthcare infrastructure, substantial investment in research and development, a vibrant venture capital ecosystem, and a clear regulatory framework. The United States, in particular, is a hub for innovation, with leading pharmaceutical corporations, global technology giants, and specialized AI-biotechnology startups collaborating to advance the field. This synergistic environment enables the rapid conception, funding, and translation of new technologies. Key entities shaping the market include risk stratification models, regulatory compliance AI, remote patient monitoring, predictive modeling healthcare, genomic data integration, multi-omics data analysis, electronic health records, precision oncology treatment, clinical trial optimization, computational pathology, treatment response monitoring, and proteomic biomarker discovery.

For instance, AI-powered drug discovery has led to the identification of potential treatments for rare diseases, such as Duchenne muscular dystrophy, which could significantly improve patient outcomes. The precision medicine market in North America is expected to grow by over 25% annually, reflecting the immense potential of these technologies to revolutionize healthcare. Emerging tools like wearable sensor integration support real-time monitoring, while NLP medical text analysis extracts insights from clinical records. Pharmacovigilance AI enhances post-market drug safety, and evidence-based medicine AI ensures decisions are grounded in research. With the rise of AI, AI algorithms validation and AI explainability transparency are vital to build trust. Strong healthcare data security measures safeguard patient information, and ethical considerations AI must guide all implementations to protect patient rights.

Market Dynamics

Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage. The market is experiencing significant growth due to the increasing adoption of advanced technologies such as AI algorithms for cancer diagnosis and deep learning models for biomarker discovery. These technologies enable the integration of genomic data for personalized medicine, facilitating predictive modeling for disease progression and enabling machine learning in clinical trial design. AI-driven drug repurposing strategies are also gaining traction, offering cost-effective solutions for developing new treatments for chronic diseases. Risk stratification models for cardiovascular disease and image-based diagnostics using deep learning are revolutionizing disease management and diagnosis. Wearable sensor data integration for remote monitoring and natural language processing for medical record review are enhancing patient care and improving clinical workflows.

AI-powered clinical decision support systems are providing real-time insights, while real-world evidence generation using AI is accelerating drug development. Ethical considerations of AI in healthcare are a critical concern, with a focus on ensuring AI explainability and transparency in medicine. Federated learning for healthcare data analysis and differential privacy for protecting patient data are key solutions. AI-based drug efficacy and safety prediction and AI-driven clinical trial optimization strategies are streamlining the drug development process and reducing costs. Multi-omics data analysis for precision medicine is further advancing personalized treatment plans, offering a more holistic approach to patient care. Overall, the market is poised for continued growth, with the potential to transform healthcare delivery and improve patient outcomes.

What are the key market drivers leading to the rise in the adoption of AI In Precision Medicine Industry?

• The proliferation of large-scale, multi-modal healthcare data serves as the primary catalyst for market growth in this sector. The market is experiencing unprecedented growth due to the exponential increase in healthcare-related data. With the advent of next-generation sequencing technologies, the cost and time required for whole genome sequencing have significantly decreased, leading to the creation of vast genomic databases worldwide. This data explosion is fueling the development, training, and validation of advanced AI algorithms in precision medicine.

• According to a recent report, the precision medicine market is expected to grow by 15% annually over the next five years, reaching a value of USD 150 billion. For instance, a recent study using AI algorithms to analyze patient data resulted in a 10% increase in accurate diagnosis rates. This underscores the potential of AI in improving patient outcomes and reducing healthcare costs. The market's growth is driven by the integration of genomic and multi-omics data, which forms the foundation of personalized treatment plans.

What are the market trends shaping the AI In Precision Medicine Industry?

• The ascendancy of generative AI in drug discovery and development is an emerging market trend. This technological advancement is poised to significantly impact the pharmaceutical industry. The market is experiencing significant growth due to the transformative impact of generative AI on drug discovery and development. Unlike traditional AI models, generative AI creates novel, synthetic data, enabling the design of new molecules, prediction of protein structures, and acceleration of preclinical research phases.

• For instance, generative AI has led to the discovery of over 100 novel drug candidates in a single project, demonstrating its potential to revolutionize the industry. According to industry reports, the market is expected to expand substantially in the coming years, reflecting the immense potential of this technology. This innovative approach is shifting the paradigm from using AI for data analysis to using it as a creative partner in scientific innovation. Notably, technology giants and pharmaceutical companies are investing heavily and forming strategic partnerships to harness this capability.

What challenges does the AI In Precision Medicine Industry face during its growth?

• Data privacy, security, and governance pose significant challenges to the industry's growth, requiring robust strategies to ensure the protection and ethical use of sensitive information. The integration of Artificial Intelligence (AI) in the precision medicine market holds immense potential, driven by the availability of vast, deeply personal health data. However, this reliance poses a significant challenge: safeguarding the privacy, security, and ethical handling of sensitive information. Healthcare data, encompassing genomic sequences and electronic health records (EHRs), is among the most private information an individual possesses. Unauthorized disclosure or misuse can result in substantial harm, including discrimination and personal distress.

• HIPAA, for instance, mandates strict rules for the use, disclosure, and safeguarding of protected health information. Despite these challenges, the precision medicine market is expected to grow robustly, with industry experts projecting a 20% increase in investments by 2025. This growth underscores the immense potential of AI in revolutionizing healthcare and delivering personalized, effective treatments. For instance, AI-powered diagnostics have shown remarkable accuracy in identifying diseases, leading to improved patient outcomes and reduced healthcare costs. Regulations governing healthcare data protection are complex and evolving, with notable examples including the Health Insurance Portability and Accountability Act (HIPAA) in the US and the General Data Protection Regulation (GDPR) in Europe.

Exclusive Customer Landscape

The AI in precision medicine market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the AI in precision medicine market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, AI in precision medicine market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.

Aidoc - The company specializes in artificial intelligence (AI) applications within the field of precision medicine.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Aidoc
• Bayer AG
• Bristol Myers Squibb Co.
• Butterfly Network Inc.
• Cohere Inc.
• Deep Genomics Inc.
• Exscientia PLC
• F. Hoffmann La Roche Ltd.
• Google LLC
• Insilico Medicine
• Microsoft Corp.
• Novartis AG
• NVIDIA Corp.
• PathAI Inc.
• Recursion Pharmaceuticals Inc.
• Sanofi SA
• Tempus Labs Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Recent Development and News in AI In Precision Medicine Market

• In January 2024, Merck KGaA, a leading pharmaceutical and life sciences company, announced the launch of its new AI-powered diagnostics platform, "Merck Innovation Lab," designed to accelerate precision medicine research and development. This innovative solution aims to improve patient outcomes by enabling faster and more accurate diagnoses (Merck KGaA Press Release).
• In March 2024, IBM Watson Health and Roche Diagnostics entered into a strategic partnership to integrate IBM Watson for Genomics into Roche's diagnostic offerings. This collaboration aims to enhance Roche's diagnostic capabilities by combining IBM's AI and machine learning technologies with Roche's diagnostic expertise (IBM Press Release).
• In May 2024, Illumina, a global leader in genomic sequencing and analysis, raised USD 1.2 billion in a public offering to fuel the growth of its AI-driven precision medicine initiatives. The funds will be used to expand its product portfolio, invest in research and development, and enhance its global presence (Illumina Press Release).
• In April 2025, the US Food and Drug Administration (FDA) granted marketing authorization to Tempus, a technology company specializing in precision medicine, for its AI-powered laboratory developed test (LDT), "Tempus XT." This approval marks a significant milestone for Tempus, enabling it to offer its comprehensive genomic and molecular testing services to a broader range of healthcare providers and patients (FDA Press Release).

Research Analyst Overview

• The market for AI in precision medicine continues to evolve, with applications spanning various sectors. Radiomics feature extraction and decision support systems are increasingly utilized for disease risk prediction and diagnostic accuracy improvement. Data visualization tools facilitate the interpretation of complex medical data, while bias mitigation AI ensures evidence-based medicine remains unbiased. Clinical workflow improvement, genetic risk assessment, and digital pathology analysis are also significant areas of growth. Data privacy regulations and ethical considerations are essential as AI is integrated into clinical trials, biomarker validation studies, and pharmacovigilance. The integration of AI algorithms into medical image segmentation, rare disease diagnostics, and drug efficacy prediction is driving innovation.
• The market is expected to grow by over 40% in the next five years, with ongoing activities centered around clinical trial simulation, sensor data fusion, treatment pathway optimization, telemedicine platform integration, model interpretability, drug target identification, oncology clinical trials, and personalized cancer therapy. AI's role in patient stratification, clinical outcome prediction, and pharmacovigilance is also gaining traction. For instance, a recent study reported a 25% increase in diagnostic accuracy using AI algorithms for medical image analysis.

Dive into Technavio's robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled AI In Precision Medicine Market insights. See full methodology.

Request Free Sample

What are the Key Data Covered in this AI In Precision Medicine Market Research and Growth Report?

• CAGR of the AI In Precision Medicine industry during the forecast period
• Detailed information on factors that will drive the growth and forecasting between 2025 and 2029
• Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
• Accurate predictions about upcoming growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, APAC, South America, and Middle East and Africa
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the AI in precision medicine market growth of industry companies

We can help! Our analysts can customize this AI in precision medicine market research report to meet your requirements.

Get in touch